RetinAI’s technology accelerated large-scale analysis of fluid dynamics in a Real-World, neovascular Age-related Macular Degeneration (nAMD) national database
Bern, Switzerland and Boston, U.S.A, March 2, 2023
RetinAI Medical AG (“RetinAI”), a leader in management and analysis of healthcare data through AI, empowered decision making and digital precision medicine through software., provided its CE-marked AI tools for fluid quantification to support the analysis in a large scale, multicenter, real-world national database of neovascular Age related Macular Degeneration (nAMD) patients. Four-hundred and fifty-two (452) treatment-naive eyes from 391 patients from the Fight Retinal Blindness! (FRB!) nAMD module were retrospectively evaluated over 12 months of follow up, analyzing fluid dynamics for intraretinal (IRF), subretinal (SRF) fluid and pigment epithelium detachment (PED). The study was organized by Dr. Javier Zarranz-Ventura from the Hospital Clinic de Barcelona, and a large group of investigators in Spain, who participated in the FRB! Registry. The results of the study were recently published in the British Journal of Ophthalmology on January 10, 2023 in the paper titled Artificial intelligence-based fluid quantification and associated visual outcomes in a real-world, multicentre neovascular age-related macular degeneration national database.
In the past, retinal fluid dynamics have been studied using data from clinical studies or a single centre real-world clinical setting, however this study is the first-of-its-kind to our knowledge to examine the dynamics of retinal fluid on clinical outcomes in a large, multicentre real-world clinical setting for nAMD. The study evaluated the relationship between measures of IRF, SRF and PED and visual outcomes to define baseline OCT-based patient profiles to predict vision outcomes at 12 months. Baseline IRF and PED are associated with worse baseline and final VA at 12 months, while baseline foveal, parafoveal, perifoveal SRF and perifoveal IRF predicted greater VA gains at 12 months. This study demonstrates that volumetric measures derived from AI-based segmentation of OCT volumes provide useful information for clinicians to consult their patients at diagnosis. “We feel tools like RetinAI’s AI for fluid quantification help researchers and clinicians evaluate their datasets at a much larger scale. We also are able to understand the relationship between automatically quantified biomarkers and visual outcomes, enabling advances in our understanding of nAMD how to optimize patient care”, says Sandro De Zanet, PhD, Chief Scientific Officer of RetinAI.
RetinAI Medical AG (RetinAI), founded in early 2017, is a Swiss company developing software solutions to accelerate clinical, research and pharmaceutical workflows globally using advanced machine learning and computer vision. RetinAI builds tools to collect, organize and analyze health data from the eyes, enabling healthcare professionals to make the right decisions sooner in healthcare. RetinAI's international team leverages its clinical, technical, and scientific expertise to foster the transition from reactive to preventive medicine for severe eye diseases. www.retinai.com